Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EXELIXIS, INC. Director's Dealing 2020

Sep 25, 2020

30561_dirs_2020-09-24_35cd7176-0158-48f8-bfc0-21b15716da05.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2020-09-22

Reporting Person: Hessekiel Jeffrey (EVP and General Counsel)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-09-22 Common Stock M 10258 $7.27 Acquired 353284 Direct
2020-09-22 Common Stock S 10258 $26.14 Disposed 343026 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-09-22 Option (right to buy) $7.27 M 10258 Disposed 2021-02-09 Common Stock (10258.0) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 999 Indirect

Footnotes

F1: Includes 39,058 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020.

F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.30. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

F4: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of September 21, 2020.

F5: The option, representing the right to purchase a total of 230,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 10, 2018.